Enzo Biochem Competitors

Enzo Biochem (NYSE:ENZ) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Enzo Biochem and Celcuity, as reported by MarketBeat.com.

Celcuity has a consensus target price of $27.00, indicating a potential upside of 8.70%. Given Celcuity's higher probable upside, analysts clearly believe Celcuity is more favorable than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Celcuity's net margins, return on equity and return on assets.

Insider and Institutional Ownership

60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 18.6% of Celcuity shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by company insiders. Comparatively, 43.5% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Enzo Biochem and Celcuity's gross revenue, earnings per share and valuation.

Celcuity has lower revenue, but higher earnings than Enzo Biochem.

Risk & Volatility

Enzo Biochem has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Summary

Celcuity beats Enzo Biochem on 6 of the 11 factors compared between the two stocks.

Enzo Biochem (NYSE:ENZ) and Centogene (NASDAQ:CNTG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Enzo Biochem and Centogene, as reported by MarketBeat.com.

Centogene has a consensus target price of $20.00, indicating a potential upside of 63.27%. Given Centogene's higher probable upside, analysts clearly believe Centogene is more favorable than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Centogene's net margins, return on equity and return on assets.

Insider and Institutional Ownership

60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 15.8% of Centogene shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Enzo Biochem and Centogene's gross revenue, earnings per share and valuation.

Centogene has lower revenue, but higher earnings than Enzo Biochem.

Risk & Volatility

Enzo Biochem has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Centogene has a beta of -2.25, indicating that its stock price is 325% less volatile than the S&P 500.

Summary

Centogene beats Enzo Biochem on 7 of the 12 factors compared between the two stocks.

Enzo Biochem (NYSE:ENZ) and Progenity (NASDAQ:PROG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Enzo Biochem and Progenity, as provided by MarketBeat.com.

Progenity has a consensus price target of $8.60, suggesting a potential upside of 122.22%. Given Progenity's higher possible upside, analysts plainly believe Progenity is more favorable than Enzo Biochem.

Earnings and Valuation

This table compares Enzo Biochem and Progenity's top-line revenue, earnings per share and valuation.

Progenity has lower revenue, but higher earnings than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Progenity's net margins, return on equity and return on assets.

Insider & Institutional Ownership

60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 17.1% of Progenity shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by insiders. Comparatively, 80.6% of Progenity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Progenity beats Enzo Biochem on 6 of the 8 factors compared between the two stocks.

Enzo Biochem (NYSE:ENZ) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 29.2% of Exagen shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by insiders. Comparatively, 48.9% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Enzo Biochem and Exagen, as provided by MarketBeat.com.

Exagen has a consensus price target of $24.25, suggesting a potential upside of 50.43%. Given Exagen's higher possible upside, analysts plainly believe Exagen is more favorable than Enzo Biochem.

Earnings and Valuation

This table compares Enzo Biochem and Exagen's top-line revenue, earnings per share and valuation.

Exagen has lower revenue, but higher earnings than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Exagen's net margins, return on equity and return on assets.

Summary

Exagen beats Enzo Biochem on 6 of the 11 factors compared between the two stocks.

Enzo Biochem (NYSE:ENZ) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider and Institutional Ownership

60.4% of Enzo Biochem shares are held by institutional investors. Comparatively, 2.3% of OpGen shares are held by institutional investors. 9.4% of Enzo Biochem shares are held by insiders. Comparatively, 0.4% of OpGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Enzo Biochem has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, OpGen has a beta of -0.44, indicating that its stock price is 144% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Enzo Biochem and OpGen, as provided by MarketBeat.

OpGen has a consensus price target of $5.50, suggesting a potential upside of 113.18%. Given OpGen's higher possible upside, analysts clearly believe OpGen is more favorable than Enzo Biochem.

Earnings & Valuation

This table compares Enzo Biochem and OpGen's top-line revenue, earnings per share and valuation.

OpGen has lower revenue, but higher earnings than Enzo Biochem.

Profitability

This table compares Enzo Biochem and OpGen's net margins, return on equity and return on assets.

Summary

Enzo Biochem beats OpGen on 7 of the 12 factors compared between the two stocks.

AnPac Bio-Medical Science (NASDAQ:ANPC) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Earnings and Valuation

This table compares AnPac Bio-Medical Science and Enzo Biochem's gross revenue, earnings per share and valuation.

AnPac Bio-Medical Science has higher earnings, but lower revenue than Enzo Biochem.

Analyst Recommendations

This is a summary of current recommendations and price targets for AnPac Bio-Medical Science and Enzo Biochem, as provided by MarketBeat.com.

Insider and Institutional Ownership

0.0% of AnPac Bio-Medical Science shares are held by institutional investors. Comparatively, 60.4% of Enzo Biochem shares are held by institutional investors. 9.4% of Enzo Biochem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares AnPac Bio-Medical Science and Enzo Biochem's net margins, return on equity and return on assets.

Summary

AnPac Bio-Medical Science beats Enzo Biochem on 6 of the 9 factors compared between the two stocks.